Conformis, Inc. – NASDAQ:CFMS
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 6 hours
Conformis stock price monthly change
+0.89%
month
Conformis stock price quarterly change
+107.34%
quarter
Conformis stock price yearly change
+769.23%
year
Conformis key metrics
Market Cap | 17.88M |
Enterprise value | N/A |
P/E | -0.25 |
EV/Sales | -0.13 |
EV/EBITDA | 0.18 |
Price/Sales | 0.20 |
Price/Book | 0.23 |
PEG ratio | N/A |
EPS | -5.71 |
Revenue | 57.06M |
EBITDA | -38.61M |
Income | -41.5M |
Revenue Q/Q | -14.85% |
Revenue Y/Y | -5.71% |
Profit margin | -81.34% |
Oper. margin | -74.58% |
Gross margin | 37.41% |
EBIT margin | -74.58% |
EBITDA margin | -67.67% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeConformis stock price history
Conformis stock forecast
Conformis financial statements
| Sep 2022 | 13.78M | -15.20M | -110.29% |
|---|---|---|---|
| Dec 2022 | 17.42M | -3.71M | -21.33% |
| Mar 2023 | 12.83M | -9.57M | -74.56% |
| Jun 2023 | 13.02M | -13.01M | -99.91% |
| Sep 2022 | 104593000 | 43.42M | 41.52% |
|---|---|---|---|
| Dec 2022 | 94048000 | 39.86M | 42.39% |
| Mar 2023 | 81923000 | 37.29M | 45.53% |
| Jun 2023 | 67781000 | 35.75M | 52.75% |
| Sep 2022 | -12.03M | -607K | 0 |
|---|---|---|---|
| Dec 2022 | -11.35M | -321K | 0 |
| Mar 2023 | -9.84M | -907K | 0 |
| Jun 2023 | -11.29M | -308K | 0 |
Conformis alternative data
| Aug 2023 | 295 |
|---|---|
| Sep 2023 | 295 |
| Oct 2023 | 295 |
| Nov 2023 | 295 |
| Dec 2023 | 295 |
| Jan 2024 | 295 |
| Feb 2024 | 295 |
| Mar 2024 | 295 |
| Apr 2024 | 295 |
| May 2024 | 295 |
| Jun 2024 | 295 |
| Jul 2024 | 295 |
Conformis other data
20.35%
-13.31%
of CFMS is owned by hedge funds
25
-10
1.46M
-970.57K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jul 2021 | 0 | 3749 |
| Aug 2021 | 0 | 12493 |
| Nov 2021 | 0 | 89953 |
| Jan 2022 | 0 | 25249 |
| Feb 2022 | 0 | 11537 |
| May 2022 | 0 | 22396 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 22,396 | $0.46 | $10,280 | ||
Sale | HOWE ROBERT S officer: CFO & TREASURER | Common Stock | 11,537 | $0.65 | $7,511 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 25,249 | $0.75 | $18,811 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 40,000 | $1.2 | $48,000 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 49,953 | $1.2 | $59,944 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 5,000 | $1.4 | $7,000 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 7,493 | $1.42 | $10,640 | ||
Sale | ALLDREDGE J BRENT officer: CLO & SE.. | Common Stock | 3,749 | $1.47 | $5,511 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 4,781 | $0.81 | $3,873 | ||
Sale | AUGUSTI MARK A director, officer.. | Common Stock | 7,311 | $0.8 | $5,812 |
| Patent |
|---|
Application Filling date: 2 Nov 2021 Issue date: 1 Sep 2022 |
Application Filling date: 7 Dec 2021 Issue date: 24 Mar 2022 |
Application Filling date: 22 Jun 2020 Issue date: 24 Mar 2022 |
Application Filling date: 18 Oct 2021 Issue date: 17 Feb 2022 |
Grant Utility: Kinematic and parameterized modeling for patient-adapted implants, tools, and surgical procedures Filling date: 18 Mar 2020 Issue date: 25 Jan 2022 |
Application Filling date: 2 Aug 2021 Issue date: 25 Nov 2021 |
Grant Filling date: 14 Sep 2018 Issue date: 19 Oct 2021 |
Application Filling date: 5 Apr 2021 Issue date: 22 Jul 2021 |
Application Filling date: 3 Mar 2021 Issue date: 24 Jun 2021 |
Application Filling date: 29 Dec 2020 Issue date: 13 May 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2023 8 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 1 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 2 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 9 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
When is Conformis's next earnings date?
Unfortunately, Conformis's (CFMS) next earnings date is currently unknown.
-
Does Conformis pay dividends?
No, Conformis does not pay dividends.
-
How much money does Conformis make?
Conformis has a market capitalization of 17.88M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 37.86% to 62.05M US dollars.
-
What is Conformis's stock symbol?
Conformis, Inc. is traded on the NASDAQ under the ticker symbol "CFMS".
-
What is Conformis's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Conformis?
Shares of Conformis can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Conformis's key executives?
Conformis's management team includes the following people:
- Mr. Mark A. Augusti Chief Executive Officer, Pres & Director(age: 59, pay: $989,400)
- Mr. Robert S Howe Chief Financial Officer & Treasurer(age: 55, pay: $552,290)
- Mr. J. Brent Alldredge J.D. Chief Legal Officer & Corporation Sec.(age: 50, pay: $470,500)
-
How many employees does Conformis have?
As Jul 2024, Conformis employs 295 workers.
-
When Conformis went public?
Conformis, Inc. is publicly traded company for more then 10 years since IPO on 1 Jul 2015.
-
What is Conformis's official website?
The official website for Conformis is conformis.com.
-
Where are Conformis's headquarters?
Conformis is headquartered at 600 Technology Park Drive, Billerica, MA.
-
How can i contact Conformis?
Conformis's mailing address is 600 Technology Park Drive, Billerica, MA and company can be reached via phone at +7 813459001.
Conformis company profile:
Conformis, Inc.
conformis.comExchange:
NASDAQ
Full time employees:
295
Industry:
Medical - Devices
Sector:
Healthcare
Conformis, Inc., a medical technology company, develops, manufactures, and sells patient-specific products and instrumentation. The company offers personalized knee replacement products, including iUni, iDuo, a custom-made partial knee replacement option for either unicompartmental or bicompartmental osteoarthritis of the knee; iTotal CR, a cruciate retaining total knee replacement product; iTotal PS, a posterior stabilized knee replacement product, as well as provides iTotal Identity and Identity Imprint knee replacement products. It also provides Conformis Hip System and Cordera hip replacement, which are hip replacement products; and iJigs, a personalized single-use patient-specific instrumentation. The company markets and sells its products to orthopedic surgeons, hospitals, and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Spain, Portugal, the Netherlands, Belgium, the Dutch Antilles, Suriname, Australia, the United Arab Emirates, the Sultanate of Oman, Italy, Poland, and other markets. Conformis, Inc. was incorporated in 2004 and is headquartered in Billerica, Massachusetts.
600 Technology Park Drive
Billerica, MA 01821
Billerica, MA 01821
CIK: 0001305773
ISIN: US20717E1010
CUSIP: 20717E101
